PharmaVoice 100: Page 2

  • Udit Batra header with PV100 logo
    Image attribution tooltip
    Permission granted by Udit Batra
    Image attribution tooltip
    Profile // Red Jacket honorees 2022

    Red Jacket: Udit Batra

    A combination of logic and love — that’s how the CEO of Waters Corp. leads and how he inspires those around him to “solve the problems that matter.”

    By PharmaVoice staff • Sept. 15, 2022
  • Fabio Gratton header with PV100 logo
    Image attribution tooltip
    Permission granted by Fabio Gratton
    Image attribution tooltip
    Profile // Red Jacket honorees 2022

    Red Jacket: Fabio Gratton

    The serial entrepreneur has relied on his gift for storytelling, creativity and a bit of “magic” as he’s launched one successful niche tech company after another.

    By PharmaVoice staff • Sept. 15, 2022
  • Quita Highsmith header
    Image attribution tooltip
    Permission granted by Quita Highsmith
    Image attribution tooltip
    Profile

    Red Jacket: Quita Highsmith

    The VP and chief diversity officer of Genentech is driving enterprise-wide strategies to influence how the biotech giant approaches DE&I — from clinical trials to career advancement.

    By PharmaVoice staff • Sept. 15, 2022
  • Header of Peyton Howell with PV100 logo
    Image attribution tooltip
    Permission granted by Peyton Howell
    Image attribution tooltip
    Profile // Red Jacket honorees 2022

    Red Jacket: Peyton Howell

    The chief operating and growth officer of Parexel has sold her market access company and created award-winning DE&I programs, but it’s her role as “connector” that she takes the greatest pride in.

    By PharmaVoice staff • Sept. 15, 2022
  • A portrait of Jim Lang framed with a banner icon that reads "PV 100"
    Image attribution tooltip
    Permission granted by Jim Lang
    Image attribution tooltip
    Profile // Red Jacket honorees 2022

    Red Jacket: Jim Lang

    The CEO of Eversana has made his mark on the life sciences by disrupting the status quo for commercialization — and he’s got more industry-shifting changes in the works.

    By PharmaVoice staff • Sept. 15, 2022
  • Header image for Red Jacket Awards
    Image attribution tooltip
    Shaun Lucas/PharmaVoice
    Image attribution tooltip

    The 2022 Red Jacket honorees

    Our annual PharmaVoice 100 “hall of fame” winners raise the bar on transformative leadership in life sciences.

    Sept. 15, 2022
  • A portrait of Abigail Jenkins framed with a banner icon that reads "PV 100"
    Image attribution tooltip
    Permission granted by Abigail Jenkins
    Image attribution tooltip
    Profile // PharmaVoice 100

    Disrupters: Abigail Jenkins

    With the belief that empathy is critical to leadership, the former chief commercial and business officer of Lyndra Therapeutics has a strong track record of building teams and accelerating progress.

    By • Sept. 6, 2022
  • A portrait of Adrelia Allen framed with a banner icon that reads "PV 100"
    Image attribution tooltip
    Permission granted by Adrelia Allen
    Image attribution tooltip
    Profile // PharmaVoice 100

    DE&I Champions: Adrelia Allen

    Merck & Co.’s senior director of clinical trial patient diversity is transforming the pharma giant’s approach to inclusion and equality.

    By PharmaVoice staff • Sept. 6, 2022
  • A portrait of Amanda Ryan framed with a banner icon that reads "PV 100"
    Image attribution tooltip
    Permission granted by Amanda Ryan
    Image attribution tooltip
    Profile // PharmaVoice 100

    DE&I Champions: Amanda Ryan

    G3 Life Sciences’ president is lighting a fire to increase access to healthcare and diversity in trials.

    By PharmaVoice staff • Sept. 6, 2022
  • A portrait of Dr. Amy C. Peterson framed with a banner icon that reads "PV 100"
    Image attribution tooltip
    Permission granted by Dr. Amy C. Peterson
    Image attribution tooltip
    Profile // PharmaVoice 100

    Innovators: Dr. Amy Peterson

    The president and chief operating officer of CytomX is fighting to change the course of cancer as a leader in cutting-edge treatments.

    By PharmaVoice staff • Sept. 6, 2022
  • A portrait of Andrew Miller framed with a banner icon that reads "PV 100"
    Image attribution tooltip
    Permission granted by Andrew Miller
    Image attribution tooltip
    Profile // PharmaVoice 100

    Entrepreneurs: Andrew Miller

    The founder and COO of Karuna Therapeutics is leveraging a combination of persistence and adaptability to scale up the biopharmaceutical company.

    By PharmaVoice staff • Sept. 6, 2022
  • A portrait of Ann Barnes framed with a banner icon that reads "PV 100"
    Image attribution tooltip
    Permission granted by Ann Barnes
    Image attribution tooltip
    Profile // PharmaVoice 100

    DE&I Champions: Ann Barnes

    The CEO of Intelligent Medical Objects is growing her company’s diversity initiatives — and its bottom line.

    By PharmaVoice staff • Sept. 6, 2022
  • A portrait of Armon Sharei framed with a banner icon that reads "PV 100"
    Image attribution tooltip
    Permission granted by Armon Sharei
    Image attribution tooltip
    Profile // PharmaVoice 100

    Entrepreneurs: Armon Sharei

    The CEO of SQZ Biotech is leveraging a technology platform that is simple in its design yet targeted at making cell therapy to break down barriers to the treatments.

    By • Sept. 6, 2022
  • A portrait of Baba Shetty framed with a banner icon that reads "PV 100"
    Image attribution tooltip
    Permission granted by Baba Shetty
    Image attribution tooltip
    Profile // PharmaVoice 100

    Tech Wizards: Baba Shetty

    The pragmatic president of technology and data solutions at Syneos Health helps healthcare companies do what they imagine.

    By • Sept. 6, 2022
  • A portrait of Barbara Klencke framed with a banner icon that reads "PV 100"
    Image attribution tooltip
    Permission granted by Barbara Klencke
    Image attribution tooltip
    Profile // PharmaVoice 100

    Innovators: Dr. Barbara Klencke

    The chief medical officer at Sierra Oncology, a GSK company, is working to make high-impact changes for rare cancer patients.

    By • Sept. 6, 2022
  • A portrait of Dr. Barbara Wirostko framed with a banner icon that reads "PV 100"
    Image attribution tooltip
    Permission granted by Dr. Barbara Wirostko
    Image attribution tooltip
    Profile // PharmaVoice 100

    Entrepreneurs: Dr. Barbara Wirostko

    Qlaris Bio’s CMO and co-founder has her sights on bringing life-changing treatments to patients with debilitating eye diseases.

    By PharmaVoice staff • Sept. 6, 2022
  • A portrait of Ben Yerxa framed with a banner icon that reads "PV 100"
    Image attribution tooltip
    Permission granted by Ben Yerxa
    Image attribution tooltip
    Profile // PharmaVoice 100

    Entrepreneurs: Ben Yerxa

    The CEO in retinal diseases sees opportunities for drug development success by merging the work of a gene therapy startup with venture philanthropy.

    By • Sept. 6, 2022
  • A portrait of Beth Crouse framed with a banner icon that reads "PV 100"
    Image attribution tooltip
    Permission granted by Beth Crouse
    Image attribution tooltip
    Profile // PharmaVoice 100

    Entrepreneurs: Beth Crouse

    The 2nd Spark CEO is on a mission to create ‘brand fans’ and bring meaningful marketing experiences to healthcare.

    By PharmaVoice staff • Sept. 6, 2022
  • A portrait of Bobak Azamian framed with a banner icon that reads "PV 100"
    Image attribution tooltip
    Permission granted by Bobak Azamian
    Image attribution tooltip
    Profile // PharmaVoice 100

    Entrepreneurs: Dr. Bobak Azamian

    The CEO is bringing his vision for innovative eye therapies to Tarsus Pharmaceuticals.

    By • Sept. 6, 2022
  • A portrait of Carl Turner framed with a banner icon that reads "PV 100"
    Image attribution tooltip
    Permission granted by Carl Turner
    Image attribution tooltip
    Profile // PharmaVoice 100

    Disrupters: Carl Turner

    How Klick’s first-ever chief brand strategy officer is relying on collaboration to advance innovative strategies for clients and opportunities for people of color.

    By • Sept. 6, 2022
  • A portrait of Carol Lynch framed with a banner icon that reads "PV 100"
    Image attribution tooltip
    Permission granted by Carol Lynch
    Image attribution tooltip
    Profile // PharmaVoice 100

    Legacy Leaders: Carol Lynch

    The chief business officer for Sandoz combines a shrewd business sense with a generous approach to leadership.

    By Alexandra Pecci • Sept. 6, 2022
  • A portrait of Charlene Stern framed with a banner icon that reads "PV 100"
    Image attribution tooltip
    Permission granted by Charlene Stern
    Image attribution tooltip
    Profile // PharmaVoice 100

    Disrupters: Charlene Stern

    How the chief lawyer of Editas Medicine is using a multi-lens approach to bolster the development of game-changing genomic medicines.

    By PharmaVoice staff • Sept. 6, 2022
  • A portrait of Chris Round framed with a banner icon that reads "PV 100"
    Image attribution tooltip
    Permission granted by Chris Round
    Image attribution tooltip
    Profile // PharmaVoice 100

    Legacy Leaders: Chris Round

    The president of EMD Serono, the U.S. and Canadian healthcare business unit of Merck KGaA, Darmstadt, Germany, has the company firing on all cylinders for near- and long-term growth.

    By PharmaVoice staff • Sept. 6, 2022
  • A portrait of Dr. Cristian Massacesi framed with a banner icon that reads "PV 100"
    Image attribution tooltip
    Permission granted by Dr. Cristian Massacesi
    Image attribution tooltip
    Profile // PharmaVoice 100

    Innovators: Dr. Cristian Massacesi

    With the goal of redefining how medicines are made, the CMO and oncology CDO is transforming AstraZeneca’s oncology development.

    By • Sept. 6, 2022
  • A portrait of David Katz framed with a banner icon that reads "PV 100"
    Image attribution tooltip
    Permission granted by David Katz
    Image attribution tooltip
    Profile // PharmaVoice 100

    Entrepreneurs: David Katz

    As the founder and chief scientific officer of Sparrow Pharmaceuticals, David Katz is breathing new life into drugs that have previously been shelved.

    By • Sept. 6, 2022